Skip to main content

Table 1 SCr levels in the LTE and Phase 3 studies: number (percentage) of patients with maximum confirmed increase in SCr in the LTE studies versus increase at EoT in the Phase 3 studies

From: Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials

SCr increase at EoT in Phase 3 (%) LTE study: maximum percentage confirmed increase in creatinine (n = 1,651)
≤10% >10 to <33% ≥33 to ≤50% >50% Total
≤10% 634 (69.8) 264 (29.0) 9 (1.0) 2 (0.2) 909 (100.0)
>10 to <33% 208 (31.9) 395 (60.5) 43 (6.6) 7 (1.1) 653 (100.0)
≥33 to ≤50% 24 (29.3) 28 (34.2) 24 (29.3) 6 (7.3) 82 (100.0)
>50% 0 (0.0) 2 (28.6) 2 (28.6) 3 (42.9) 7 (100.0)
  1. EoT, end of treatment; LTE, long-term extension; SCr, serum creatinine.